T cells, especially Ag-specific cytotoxic T cells, can detect and eliminate cancer cells through the recognition of tumor-associated Ags, such as neoantigens. Neoplastic cells, however, evade immune surveillance through various mechanisms. For example, tumor-infiltrating T cells often fail to eliminate cancer because of an immunosuppressive tumor microenvironment that induces a dysfunctional state, characterized by the expression of multiple inhibitory receptors such as programmed cell death protein 1 (PD1), TIM3, and CTLA4, and designated as exhausted T cells (T EXH ). Importantly, Abs targeting CTLA-4 and PD1 have demonstrated dramatic therapeutic benefit in various cancer types, correlating with their ability to enhance effector T cell (T EFF ) function (1) . However, these immunotherapy strategies are successful in only a subset of patients. Although multiple mechanisms likely account for a failure to respond to immune checkpoint inhibitory therapy, the inherent immunogenicity of a patient's tumor and corresponding levels of pre-existing tumor-reactive T cells present at the start of therapy have emerged as important factors governing the response (2) . For instance, patients with lower mutation burden and/or with scarce T cell infiltration in their tumors generally have poor responses to immune checkpoint inhibitors (3, 4) .
Given the potential limitations of immune checkpoint inhibitory therapy in patients with low pre-existing antitumor immunity, an alternative promising therapeutic strategy involves mobilizing polyclonal T cells against tumor cells in an MHC-peptide presentation-independent manner. Two such clinically successful approaches include adoptive cell therapy with chimeric Ag receptor (CAR) T cells (5, 6) and the use of bispecific T cell engager (BiTE) Ab constructs (7) . CAR T therapy involves engineering autologous T cells to express a chimeric receptor that is capable of recognizing tumor-associated surface Ag to trigger T cell activation, whereas BiTE Ab constructs are a novel class of immunotherapy molecules engineered to redirect T cells to tumor sites and induce T cell activation, immune synapse formation, and ultimately tumor cell killing, regardless of Ag specificity (5) (6) (7) . BiTE molecules contain two fused single-chain variable fragments, with one that binds to CD3 on T cells and the other that binds to a tumor-associated Ag (7) .
Blinatumomab, a CD19/CD3 BiTE Ab construct, is the first BiTE molecule approved by the U.S. Food and Drug Administration to treat various hematologic malignancies (8) . Although this therapy provides evidence that BiTE molecules can induce robust tumor cell killing in humans, the degree to which this activity will translate to the solid tumor setting is largely unknown. PD1-expressing T EXH represent a dominant phenotype among solid tumor-infiltrating CD8 + T cells (1) , and PD1 is known to be induced by BiTE molecule treatment in vitro (9, 10) . This suggests that the PD1/programmed death ligand 1 (PDL1) pathway may potentially interfere with BiTE molecule activity in solid tumors and provides a rationale for combining BiTE molecules with PD1 inhibitors. However, other CD8 + T cell subsets beyond T EXH are found within solid tumors (11, 12) . Further dissecting the function of these populations and their ability to respond to BiTE molecule engagement may lead to additional combination therapy approaches aimed at eradicating solid tumors.
The human peripheral blood CD8 + T cell compartment is comprised of multiple subsets, often distinguished by their expression of the naive/memory marker CD45RA and the chemokine receptor CCR7. CD8 + naive T cells (T N ) are CD45RA + CCR7 + , whereas CD8 + effector memory T cells (T EM ) are CD45RA 2 CCR7 +/2 . Previous studies have demonstrated that CD8 + T EM contribute to BiTE molecule activity among peripheral blood CD8 + T cell subsets, whereas CD8 + T N show minimal response to BiTE molecule treatment (13) . In addition, blocking PD1 has been shown to mainly expand the intratumoral effector memory subset of CD8 + T cells in patients (14) . An additional Ag-experienced CD8 + T cell population is defined as CD45RA + CCR7 2 (effector memory T cells reexpressing CD45RA [T EMRA ]). These effector cells have high cytotoxicity, high sensitivity to apoptosis, low IL-2 production (15), and represent a significant CD8 + T cell population in elderly individuals and cancer patients (16, 17) . However, the degree to which T EMRA can efficiently mediate BiTE molecule-induced tumor killing, the function of these cells within solid tumors, and the mechanisms regulating their activity, remain largely unknown.
In this study, we studied the phenotype of Ag-experienced CD8 + T cell subsets isolated from human peripheral blood and solid tumor biopsy specimens, their function following BiTE molecule treatment, and the mechanisms regulating their activity. In blood, we identify T EMRA as the subset with the most potent cytolytic activity following BiTE molecule engagement and find that a subset of these cells expressing high levels of cytolytic effector molecules also expresses the ITIM-containing inhibitory leukocyte Ig-like receptor B1 (LILRB1), which can function as a negative regulator of BiTE molecule-induced tumor cell killing. Importantly, LILRB1 and PD1 showed nonoverlapping expression patterns across CD8 + T EM and T EMRA subsets, and blocking both pathways synergistically enhanced CD8 + T cell function. We extend these data from peripheral blood to tumor-associated T cell populations, demonstrating similar phenotypic and functional properties of T EMRA . These data highlight the potential importance of T EMRA in antitumor immune surveillance and BiTE molecule-mediated activity against solid tumors and suggest that blockade of LILRB1 may be a promising therapeutic approach to enhance their cytolytic activity.
Materials and Methods

Abs and flow cytometry
The following Abs were used: CD3 (Sk7; eBioscience), CD4 (OKT4; Bio-Legend), CD8 (RPA-T8; BD Biosciences), CCR7 (G043H7; BioLegend), CD45RA (HI100; BioLegend), LILRB1(GHI/75; BioLegend), PD1 (EH12.1; BD Biosciences), CD69 (FN50; BD Biosciences), granzyme B (GB11; BioLegend) and perforin (B-D48; BioLegend), HLA-G (MEM-G/9; Thermo Fisher Scientific). LIVE/DEAD Fixable Viability Dye eFluor 506 (eBioscience), or SYTOX Blue (Thermo Fisher Scientific) was included to mark dead cells. For staining of cell surface proteins, cells were incubated with appropriate Ab mixtures for 30 min at 4˚C. To determine expression of intracellular proteins, cells were fixed for 30 min at 4˚C using the Foxp3 Transcription Factor Staining Buffer Set (catalog no. 00-5523-00; Thermo Fisher Scientific) following the manufacturer's protocol. Subset cell population was isolated by cell sorting with a BD FACSAria cytometer (BD Biosciences). Data acquisition of Ab-stained samples was carried out on an LSR II (BD Biosciences) and analyzed with FlowJo software v10.3 (Tree Star).
Primary human cell assays
Human PBMCs from healthy volunteers were obtained after informed consent and authorized by the Amgen Research Blood Donor Program. PBMCs were isolated by density gradient centrifugation (Ficoll-Paque PREMIUM, catalog no. 17-5442-02; GE Healthcare). Cell subsets were isolated from PBMCs with appropriate magnetic beads following manufacturer's protocol (STEMCELL Technologies) or by cell sorting with a BD FACSAria cytometer. Isolated human primary lymphocytes were cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin and streptomycin, and 2-ME (all from Life Technologies) at 37˚C. PBMCs were stimulated with 10 ng/ml recombinant human IL-2 (catalog no. 202-IL-010/CF), 10 ng/ml recombinant human IL-15 (catalog no. 247-ILB-025/CF), or 100 ng/ml recombinant human TNF (catalog no. 210-TA-020/CF) (all from R&D Systems) and then subjected to flow cytometry analysis. Isolated T cells were activated with platebound anti-CD3 (OKT3, 5 mg/ml; BD Biosciences) plus soluble anti-CD28 (CD28.2, 2 mg/ml; BD Biosciences). When indicated, 10 mg/ml recombinant human PDL1 (catalog no. 762506; BioLegend) or the same amount of human IgG1 isotype control Ab (catalog no. 403501; Bio-Legend) was added in culture medium. Samples were analyzed by flow cytometry. Cytokine concentrations were measured in cell culture supernatants 48 h after stimulation with Luminex assay (EMD Millipore, Billerica, MA).
Human tumor dissociation
All human tumor specimens were collected under Institutional Review Board approval with appropriate informed consent. In all cases, materials obtained were surplus to standard clinical practice. Patient identity and protected health information/identifying information were redacted from tissues and clinical data. Biopsy specimens were mechanically disrupted and incubated with 200 mg/ml Liberase TL (catalog no. 5401020001; Roche) and 20 U/ml DNase I (catalog no. 4716728001; Roche) at 37˚C for 15 min followed by tissue disaggregation using gentleMACS Octo Dissociator (Miltenyi Biotec). Cell suspension was then passed through a 70-mm filter twice and washed with DMEM/F12 containing 10% FBS (Life Technology, Carlsbad, CA).
Cell lines
SK-MEL-2 (SK2; catalog no. HTB-68, SK2; American Type Culture Collection) and SK-MEL-5 (catalog no. HTB-70, SK5; American Type Culture Collection) were maintained EMEM (catalog no. ; American Type Culture Collection) with 10% FBS and 1% penicillin/ streptomycin. HLA-G-expressing SK2 (SK2.HLA-G) cells with stable expression of human HLA-G were established by retroviral transduction. The HLA-G-b2 microglobulin cDNA was inserted into retrovirus vector pLHCX2 (catalog no. 631503; Clontech) and was cotransfected with Lipofectamine 3000 (catalog no. L3000001; Thermo Fisher Scientific) into GP2-293 packaging cells (catalog no. 631458; Clontech) with pVSV-G (catalog no. 631530; Clontech). Supernatants were collected 48 h after transfection and filtered. Then, SK2 cells were transduced with a mixture of viral supernatant with polybrene at 5 mg/ml (catalog no. TR-1003-G; EMD Millipore). After spin transduction for 1.5 h at 1200 g, 32˚C, fresh media was added. The human PDL1 cDNA was inserted into expression vector pcDNA3.1/Zeo(+) and was transfected into parental SK2 cells or SK2.HLA-G cells with Lipofectamine 3000 (Thermo Fisher Scientific). PDL1 and HLA-G expression was confirmed by flow cytometry.
MLR
Isolated human total T cells were seeded into round-bottom 96-well plates (Corning) at 1 3 10 5 per well together with 2 3 10 4 irradiated allogeneic CD11c + cells. When indicated, 10 mg/ml of anti-PD1 (clone EH12.2H7, catalog no. 329902; BioLegend) or anti-LILRB1 (clone GHI/75, catalog no. 333704; BioLegend) or both Abs were added to the culture. As control, 10 mg/ml of each matched isotype Abs were used as control. Day 5 supernatants were collected, and IFN-g level was determined by ELISA (catalog no. 550612; BD Biosciences).
Cytotoxicity assay
Sorted CD8 + T cells from healthy donor PBMCs expressing indicated markers or total CD8 + T cells from non-small cell lung cancer (NSCLC) biopsy specimens were used as T EFF cells and coincubated with tumor target cells at 4:1 ratio for the indicated time period. The BiTE molecule in this assay is CD3/melanoma Ag recognized by T cells 1 (MART-1) BiTE Ab construct (Amgen). When indicated, 25 mg/ml anti-LILRB1 (clone GHI/75; BioLegend) or 10 mg/ml of anti-PD1 (clone EH12.2H7; Bio-Legend) were added in the assay. After the culture, T cells were removed by washing with warm media, and target cell killing was determined from measuring the number of viable target cells by adding CellTiter-Glo (catalog no. G7570; Promega). Luminescence units (measured in relative light units [RLUs]) were measured by EnVision 2104 multilable reader (PerkinElmer). Percentage of specific lysis was calculated as follows: % Specific Cytotoxicity = [1 2 (RLU live target cells + BiTE molecule)/ (mean RLU live target cells 2 BiTE molecule)] 3 100.
Cell culture and cytotoxic function assay of MelanA-specific Mel-13 CD8 + T cell line
Mel-13 T cells were expanded as described (18) . Expanded Mel-13 T cells (.50% LILRB1 + by flow cytometry) were used as effector cells and cocultured with SK5 tumor target cells (10 4 per well) at indicated ratio. When indicated, anti-LILRB1 (GHI/75, 20 mg/ml) or same amount of isotype control Ab were added in the culture. After overnight incubation at 37˚C, T cells were removed by washing the wells with warm media. Target cell killing was determined by measuring the number of viable target cells using CellTiter-Glo (Catalog no. G7570; Promega). Luminescence, in RLUs, was measured by an EnVision 2104 Multilabel Reader (PerkinElmer). Percentage of specific lysis was calculated as follows: Percentage Specific Cytotoxicity = [1 2 (RLU live target cells + Mel-13)/ (mean RLU live target cells 2 Mel-13)] 3 100.
RNA sequencing
Global transcript expression in CCR7 + and CCR7 2 CD8 + T cells isolated from healthy donor PBMCs was assessed by RNA sequencing (RNAseq). RNAseq was performed on a cDNA library prepared from total RNA (2 mg; RNA integrity number .9.5) of each sample isolated using mirVana miRNA Isolation Kits (Ambion, Grand Island, NY) with on-column DNase treatment. Total RNA quality and concentration was determined using the Bioanalzyer (Agilent Technologies, Santa Clara, CA) and NanoDrop (Thermo Fisher Scientific, Wilmington, DE). cDNA was prepared using a modified protocol based on the Illumina Truseq RNA Sample Preparation Kit (Illumina, San Diego, CA) and the published methods for strandspecific RNAseq (19, 20) . After size selection of libraries (Pippen Prep; Sage Science, Beverly, MA), dUTP-containing cDNA strands were destroyed by digestion of USER enzymes (New England Biolabs, Ipswich, MA) followed by PCR enrichment for introduction of strand specificity. The enriched cDNA libraries were analyzed in an Agilent Bioanalyser and quantified by Quant-iT PicoGreen assays (Life Technologies). RNA sequencing reads (Illumina HiSeq platform, 75-bp paired end sequencing) were aligned to human genome build 38 and fragments per kb per million were sequenced. Fragments per kilobase of transcript per million mapped reads were determined using Array Suite software (Omicsoft, Cary, NC) and in-house software. Differential gene expression analysis was performed using DESeq V2 (21) . The RNAseq data have been submitted to National Center for Biotechnology Information Sequence Read Archive database (https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncbi.nlm.nih.gov_sra_PRJNA535519&d=DwICaQ&c= Sexio4usKrYWFsrnxgjbcQ&r=isDLOdYR9iBOWpfW7BvglA&m= 2FGyR3rJtIJMf51upHaeB-XYgRM7_qjfjweuZN6liT0&s=suTXFXS5v_ GXcmv4Ba1ju_LXZLZvdLsJKTVkmSHCdwc&e=) under the accession number PRJNA535519.
Single-cell RNA sequencing
Fresh human CD8 + T cells were sorted into LILRB1 + CCR7 2 CD45RA + , LILRB1 2 CCR7 2 CD45RA +/2 , and LILRB1 2 CCR7 + CD45RA + subsets on a BD FACSAria (BD Biosciences) to purity .95%. Each sorted cell subset was loaded on the 103 Chromium System (22) , and single-cell RNAseq libraries were generated according to the manufacturer's instructions. Sequencing was conducted on a HiSeq 4000 (sequencing performed by GENEWIZ). Each pooled sample was run in its own lane according to the 103 39 v2 Chemistry protocol. The Cell Ranger command line tools (103 Genomics v2.0.0) mkfastq script was used to convert each Illumina BCL file to FASTQ. Paired FASTQ files for each pooled sample (1 Lane) were aligned to GRCh38 human genome (v. 1.2.0 from 103 Genomics) using cellranger count script with default settings. The three CD8+ samples were then aggregated using cellranger aggr script. Using the R software package, Monocle (v2.6.1) data were transformed from raw unique molecular identifiers to normalized counts using Monocle's negbinomial.size (23) model. Cells were classified by expression of each respective gene (LILRB1, CCR7), positive if expression .1 and negative if expression ,1. The classifyCells function in Monocle was used to create the cell classification labels. The q value and p value statistics, along with fold change, were computed across the three cell classifications. Genes with a q value ,0.04 were kept. The mean expression of each gene was computed and the top 50 genes by fold change across each pairwise group were kept. The heatmap was created from mean expression values in each group using the python package seaborn "clustermap" function. Gene averages are z-scores across each gene (mean of 0 and variance of 1).
Single-cell RNAseq data visualization
All visualizations are created using R programming language (24) using ggplot2 and ggbeeswarm visualization packages (25, 26) . Statistics were computed using function from ggpubr package (27) . Each swarm plot (gene expression per cluster across cells) visualizes a single gene by custom cluster assignment with gene expression values represented as binary log plus + 0.1. Previously determined and published clusters for corresponding datasets (11, 12) were used to define clusters: T EM (hepatocellular carcinoma: CD8_Cluster5-GZMK; NSCLC: CD8_C4-GZMK); T EFF (hepatocellular carcinoma: CD8_Cluster2-CX3CR1; NSCLC: CD8_C3-CX3CR1); and T EXH (hepatocellular carcinoma: CD8_Cluster4-LAYN; NSCLC: CD8_C6-LAYN). Boxplots visualize five summary statistics (the median, two hinges, and two whiskers) and are overlaid with swarm plots of cells roughly representing the density distribution of the data points along the gene expression values. A nonparametric Kruskal-Wallis test was used to test for difference in gene expression of each gene between clusters, followed by pairwise Wilxocon rank sum test pairwise comparisons. The p values were adjusted using Benjamini-Hochberg procedure. For per patient boxplot, gene expression (log 2 (transcripts per million + 0.1)), as measured from previously published NSCLC datasets (12) , was averaged per patient for each depicted gene (NSCLC n patients = 14) . For gene expression of each gene between clusters, an ANOVA was used to analyze the differences among group means, followed by pairwise t test comparisons. The p values were adjusted using Benjamini-Hochberg procedure. Statistical plots were generated with GraphPad Prism software, and a two-sided paired or nonpaired Student t test was used to obtain p values. Sample sizes were determined based on experimental data distribution pattern.
Results
LILRB1-expressing effector CD8 + T cells can efficiently mediate BiTE molecule-induced cytolytic activity
To understand which human CD8 + T cell subset most efficiently mediates BiTE molecule-induced T cell-dependent cellular cytotoxicity, we isolated human CD8 + T N , T EM , and T EMRA subsets from peripheral blood based on expression of surface markers CD45RA and CCR7 (15) . The cytolytic activity of isolated CD8 + T cell subsets was determined using SK2 cells endogenously expressing the MART-1 tumor Ag and a MART-1-specific BiTE molecule. As shown in Fig. 1A , T EMRA were the most potent at BiTE molecule-induced killing of target cancer cells (EC50 = 25.51 pM), followed by CD45RA 2 CCR7 2 T EM (EC 50 = 58.11 pM) and CD45RA + CCR7 + T N (EC 50 = 7948 pM). T EMRA also had the highest maximum percentage of tumor cell lysis (Fig. 1A) . These data suggest that enhancing the effector function of T EMRA may further enhance BiTE moleculemediated tumor killing.
To identify regulatory pathways that modulate CTL activity, we evaluated the gene transcriptional profiles of sorted T N , T EM , central memory T cell (T CM ) and T EMRA subsets. Differential expression analysis comparing CCR7 + T N and T CM with CCR7 2 T EM and T EMRA populations revealed expression of various genes associated with CD8 + T cell function, including PRF1, GZMB, and CX3CR1 (Fig. 1B , Supplemental Table I ). In addition, LILRB1, an ITIM-containing inhibitory receptor that signals downstream of interactions with HLA-G and several classical MHC class I alleles (28) , was also found to be highly expressed by the T EMRA and T EM populations (Fig. 1B , Supplemental Table I) , with preferential expression in T EMRA (Fig. 1C) . Analysis of CD8 + T cell phenotypes by flow cytometry confirmed that the majority of T EMRA but only a small population of T EM express LILRB1 (Fig. 1D, 1E ).
LILRB1 is a marker of CD8 + T cell with potent effector function
The above data suggested that LILRB1 expression may be associated with acquisition of CD8 + T cell effector function. Indeed, ex vivo FACS analysis of peripheral blood T cells from multiple donors confirmed that the majority of CD8 + LILRB1 + T cells constitutively express perforin and granzyme B ( Fig. 2A) , whereas very few perforin-or granzyme B-expressing cells are found in LILRB1 2 T EMRA and CD8 + T EM (Fig. 2B) . Expression of effector molecules by LILRB1 + CCR7 2 , LILRB1 2 CCR7 2 , and LILRB1 2 CCR7 + CD8 + T cell subsets was also evaluated in supernatants from cultured-sorted T cells either without (Fig. 2C) or with (Fig. 2D) activation. In the absence of stimulation, LILRB1 + CCR7 2 T cells were found to secrete perforin and granzyme B to a greater extent than the other two subsets, consistent with the above FACS data. In contrast, upon TCR activation, both LILRB1 + CCR7 2 and LILRB1 2 CCR7 2 T cells were induced to produce an equal amount of granzyme B and IFN-g; however, the LILRB1 + subset still produced higher quantities of perforin compared with the LILRB1 2 population (Fig. 2D) . Interestingly, LILRB1 + CCR7 2 cells produced minimal amounts of IL-2 relative to the LILRB1 2 CCR7 2 subset. Finally, single-cell RNAseq was used to further characterize total transcripts in sorted CD8 + LILRB1 + and LILRB1 2 T cell subsets. We found that LILRB1 + cells show preferential expression of multiple genes known to be associated with T EFF , including GNLY, PRF1, GZMB, and KLRD1 ( Fig. 2E) , further supporting the finding that LILRB1 is a marker of an effector CD8 + T cell population. 
LILRB1 inhibits BiTE molecule-mediated CD8 + T cell effector function
LILRB1 has been previously shown to negatively regulate the function of NK and CD8 + T cells (29, 30) . Mel-13 is a cytolytic CD8 + T cell line that is specific for HLA A*0201 (HLA-A2)-restricted Melan-A (also known as MART-1)-derived epitope and may lyse melanoma tumor cells (18) . These cells upregulated LILRB1 expression upon expansion with appropriate feeder cells (Fig. 3A) . Blocking LILRB1 significantly enhanced Mel-13 CD8 + T cell cytolytic activity of SK-MEL-5 (HLA-A2 + ) melanoma cells (Fig. 3B) . These data suggest (Figure legend continues) that LILRB1 may function to inhibit CTL effector function and their ability to kill tumor cells. To determine if LILRB1 can regulate the function of CD8 + T EFF following stimulation with BiTE molecules, we performed a CD8 + T cell-mediated tumor cell-killing assay using SK2 target cells engineered to express HLA-G, the ligand for LILRB1, and a MART-1-specific BiTE molecule (Fig. 3C ). T EMRA were enriched from healthy donor PBMCs by flow sorting (Fig. 3D ) and were cocultured with parental SK2 cells or SK2.HLA-G cells in the presence of anti-LILRB1-blocking or control Abs. T EFF function was induced by a suboptimal concentration of the MART-1 BiTE molecule and measured as specific target cell lysis. These data demonstrate that HLA-G expression on target cells can dramatically reduce BiTE molecule-mediated T cell cytolytic activity and that this effect is reversed by LILRB1 blockade (Fig. 3E) . The presence of HLA-G on tumor cells also significantly inhibited BiTE moleculemediated upregulation of CD69 on effector CD8 + T cells (Fig. 3F, 3G) . These data indicate that LILRB1 functions as a negative regulator of CD8 + T cell effector function and that blocking LILRB1 can be used to enhance BiTE moleculemediated tumor cell killing.
We next wanted to confirm that LILRB1 was capable of inhibiting tumor-associated CD8 + T cells similar to its effect on T cells derived from peripheral blood of health donors. We isolated tumor-infiltrating CD8 + T cells from NSCLC biopsy specimens and evaluated their activity against SK2 and SK2.HLA-G target cells upon treatment with a MART-1-specific BiTE Ab construct. We found that the presence of HLA-G on the target cell significantly inhibits BiTE molecule-induced T cell activation ( Fig. 3H ) and cytolytic activity (Fig. 3I) . Inhibition of cytolytic activity can be restored with LILRB1 blockade (Fig. 3I) . These results demonstrate that LILRB1 can function as an immune checkpoint inhibitory receptor for tumor-infiltrating CD8 + T EFF and suggests that blocking LILRB1 may enhance BiTE molecule-mediated tumor CD8 + T cell cytolytic activity in patients.
Differential regulation of LILRB1 and PD1 expression in CD8 + T cells
PD1 is known to exert potent repressive activity on tumorinfiltrating CD8 + T cells, and therapeutic Abs blocking the PD1 pathway can significantly enhance T cell effector function, providing therapeutic benefit in multiple cancers (31) . Given the finding that LILRB1 can also function as negative regulator of CD8 + T cell function, we examined the regulation of LILRB1 and PD1 expression on total CD8 + T cells. We first examined LILRB1 and PD1 expression downstream of TCR signaling, confirming that PD1 is rapidly upregulated upon T cell activation. In contrast, LILRB1 expression was not sensitive to TCR signaling (Fig. 4A,  4B) . As blocking the PD1 pathway has been shown to further promote effector function of CD8 + T cells (31, 32) , we next examined whether LILRB1 expression can be regulated by PD1 signaling. Activation of CD8 + T EM in the presence of PD1 blockade resulted in an increase in the frequency of LILRB1 + effector cells, whereas the expression of PD1 was not significantly altered (Fig. 4C, 4D ). Furthermore, cytokines known to promote CD8 + T cell effector differentiation and function, such as IL-2 and IL-15 but not TNF-a, also significantly increased the frequency of LILRB1 + T cells (Fig. 4E, 4F) . Thus, signals that enhance CD8 + T cell effector function but not TCR activation alone can promote differentiation of LILRB1 + T EFF .
PD1 is preferentially upregulated on LILRB1 2 CD8 + T cells Given our findings that PD1 but not LILRB1 is upregulated on CD8 + T cells upon TCR activation, we next asked whether there is a difference in the expression of PD1 on either LILRB1 + or LILRB1 2 CD8 + T cell subsets. Upon TCR stimulation, PD1 expression was found to be preferentially upregulated on LILRB1 2 CD8 + T cells isolated from peripheral blood (Fig. 5A) . These data suggest that LILRB1 + T cells represent a unique population that may not be subject to regulation by the PD1 pathway. To extend these data to tumor-associated T cells, we analyzed publicly available single-T cell RNAseq data from hepatocellular carcinoma (11) and NSCLC (12) . In both datasets, LILRB1 and PDCD1 showed mutually exclusive expression patterns in tumor CD8 + T cells (Fig. 5B-D) . In contrast, expression patterns of other inhibitory receptor genes, such as HAVCR2 and CTLA-4, were largely overlapping with PDCD1 ( Fig. 5B, 5C ). Notably, expression levels of another HLA-G receptor KIR2DL4 (33) (Fig.5B, 5C ), as well as many other NK cell receptors (NKR) (e.g., KLRC1 and KIRs, data not shown), are low and/or less frequent in effector CD8 + T cell clusters in tumor.
We also evaluated PD1 and LILRB1 expression by flow cytometry on CD8 + T cells isolated from additional NSCLC biopsy specimens. PD1 and LILRB1 showed a heterogenous pattern of expression across tumor samples, with some samples having CD8 + T cells predominantly expressing either PD1 or LILRB1 and others having similar frequencies of LILRB1 + or PD1 + CD8 + T cells (Fig. 5E, 5F) . Nevertheless, in all the cases we examined, PD1 and LILRB1 showed a mutually exclusive expression pattern consistent with data from healthy donor T cells. Importantly, LILRB1 + CD8 + T cells represented a dominant phenotype in 4 out of 11 NSCLC tumors ( Fig. 5F ), suggesting that across patients, different inhibitory mechanisms may function to preferentially restrict antitumor T cell responses.
LILRB1 and PD1 have independent roles in restricting CD8 + T EFF function
Given the finding that LILRB1 and PD1 are expressed on different populations of CD8 + T cells and that PD1 blockade may promote differentiation of LILRB1 + T cells, we hypothesized that simultaneous blockade of LILRB1 and PD1 could lead to greater T cell activation than blockade of either pathway alone. To test this hypothesis, we engineered SK2 tumor cell lines stably expressing PDL1 (SK2.PDL1), HLA-G (SK2.HLA-G), or both molecules (SK2.PG) (Fig. 6A ). CCR7 2 CD8 + T EFF containing both LILRB1 + T EMRA and PD1 + T EM were enriched from healthy donor PBMCs by flow sorting (Fig. 6B ). As expected, target cells expressing both HLA-G and PDL1 are more resistant to BiTE molecule-induced CCR7 2 CD8 + T cell cytolytic activity than parental SK2 cells or SK2 cells expressing either PDL1 or HLA-G alone (Fig. 6C ). Consistent with these data, only the combination of anti-PD1 and anti-LILRB1 was able to fully restore CTL effector cell-killing activity against SK2.PG tumor cells expressing both HLA-G and PDL1 (Fig. 6D-G) .
In addition, evaluating the role of LILRB1 and PD1 in BiTE molecule-mediated T cell activation assays, we also performed MLR assays, comparing the effects of anti-LILRB1 or anti-PD1 alone and in combination on T cell activation. We found that the combination of anti-PD1 and anti-LILRB1 blockade leads to significantly increased IFN-g production compared with either treatment alone (Fig. 6H, 6I ). Taken together, these data indicate that LILRB1 functions as an inhibitory receptor for a unique population of PD1 2 T EFF and suggest that the combination of LILRB1 and PD1 blockade may be required to mobilize the full complement of tumor-associated CD8 + T cells to participate in the antitumor response.
Discussion
BiTE molecules have been shown to activate CD8 + T cells and enhance CTL function in vitro and in vivo (34) . The BiTE Ab construct showed translating to inhibition of solid tumor growth in preclinical mouse models (35) . However, the ability of BiTE molecules to effectively treat solid tumors in patients is still under evaluation. Major challenges associated with applying BiTE molecules to the treatment of solid tumors are the suppressive tumor microenvironment and the expression of multiple checkpoint inhibitory receptors by tumor-associated T cells that function to reduce BiTE molecule activity and thus limit their therapeutic efficacy. For example, the PD1 pathway and the presence of TGF-b or IL-10 can reduce BiTE molecule-mediated CD8 + cytolytic T cell-killing activity in vitro (35, 36) . Identifying additional regulatory pathways capable of restricting CD8 + T cell function is critical for our ability to unlock the full potential of BiTE molecule therapies and other T cell-targeted approaches in solid tumors.
In this study we identify LILRB1 as a novel checkpoint inhibitory molecule capable of restricting BiTE molecule-mediated CD8 + T cell effector function. Given the following factors: 1) LILRB1 is highly expressed by the CD8 + T EMRA subset, which is the most potent population for BiTE molecule-induced toxicity, 2) LILRB1-expressing CD8 + T cells infiltrate solid tumors, 3) HLA-G overexpression has been reported in many solid tumors, and its expression is positively associated with poor prognosis (37) , and 4) LILRB1 blockade increases CD8 + T cell cytolytic activity in vitro, these findings suggest that blocking LILRB1 may enhance BiTE molecule-mediated efficacy against solid tumors. Blocking LILRB1 may be especially important in the context of HLA-G + solid tumors, in which LILRB1-mediated inhibitory signals may be a dominant mechanism restricting cytolytic CD8 + T cell effector function. Similar to previous observations (38) , we find that LILRB1 is coexpressed with perforin and granzyme B in human CD8 + T cells. We extend these findings by performing RNAseq analysis on CD8 + T cells that were sorted based on LILRB1 expression, demonstrating that LILRB1 + CD8 + T cells preferentially express multiple effector molecules beyond perforin and granzymes. These data suggest functional specialization of the LILRB1 + T cell subset for cytolytic activity, a hypothesis consistent with findings from our BiTE molecule-mediated cytotoxicity studies. In addition to marking effector CD8 + T cells with potent cytolytic activity, we also demonstrate that LILRB1 functions as an immune checkpoint receptor, effectively inhibiting both Ag-specific CTL cytolytic activity and BiTE moleculeinduced polyclonal activation of effector CD8 + T cells.
Importantly, we find that LILRB1 and PD1 are preferentially expressed by distinct CD8 + T cell subsets in both tumor tissue and in healthy donor blood. The nonoverlapping expression of LILRB1 and PD1 in tumor-infiltrating CD8 + T cells is also observed by single-cell RNAseq analysis in multiple tumor types, including hepatocellular carcinoma (11), NSCLC (12) , and colorectal cancer (39) . Although many well-studied inhibitory receptors, such as TIM3 and CTLA-4, are coexpressed with PD1 on CD8 + T EXH in tumor, LILRB1 + CD8 + T cells are largely devoid of these inhibitory receptors. These data suggest that LILRB1 + cells are not subject to the same regulatory pathways as T EXH . Previous studies have demonstrated that NKR, such as KLRG-1, KLRC-1, and KIRs, are upregulated during CD8 + T cell differentiation toward an effector phenotype. Further analysis of published singlecell RNAseq data demonstrated that these NKRs either have low expression levels on very few CD8 + T cells, such as many KIRs, or their expression is largely not overlapping with LILRB1, such as KLRC-1. These findings suggest that LILRB1 is unique in terms of its expression and function on CD8 + T cells.
The regulation of LILRB1 gene expression is largely unknown (40) . We find that cytokines that promote T cell effector function (such as IL-2 and IL-15) but not proinflammatory cytokines, such as TNF-a, increase LILRB1 expression. Interestingly, blocking PD1 also enhances LILRB1 expression, possibly because of increased IL-2 production by T cells upon PD1 blockade. Interestingly, expression of KLRG-1, another inhibitory receptor that is highly expressed by subsets of effector CD8 + T cells, is also upregulated by IL-2 (41) . Thus, LILRB1 upregulation may serve as a negative feedback regulator for effector CD8 + T cells in response to signals that boost CD8 + T cell effector function. An implication of these data is that blocking LILRB1 will be additive/synergistic with PD1 blockade both by virtue of the ability of this therapeutic combination to activate two different CD8 + T cell subsets and the potential for anti-PD1/PDL1 therapy to increase differentiation and accumulation of LILRB1 + effector T cells, whose activity would be potentiated by anti-LILRB1.
Our study identifies LILRB1 as an inhibitory pathway that is highly differentiated from current immune checkpoint inhibitor combinations and has clear relevance as a therapeutic target capable of enhancing the efficacy BiTE molecules or other T cell-targeted approaches that are currently undergoing clinical evaluation. Moreover, our findings also generate, to our knowledge, new hypotheses beyond BiTE Ab construct therapy, suggesting that further characterization of T cell heterogeneity in tumors with respect to function and expression of inhibitory pathways may identify orthogonal mechanisms regulating distinct aspects of the antitumor T cell response, thus representing attractive targets for combination therapy approaches.
